Hemostatic system dysfunctions and carcinogenesis: State-of-the-art


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the current literature on the pathogenetic interaction of malignant neoplasms as a risk factor for thrombotic events and on the impact of hemostatic system activation on the potentiation of tumor growth and metastasis. Material and methods. The review includes the data of foreign and Russian articles published in the past 10 years and found in e-Library and PubMed, and Cochrane Library on this topic. Results. Current views are given on the pathogenetic features of functioning of the hemostatic system during tumor growth. The first category of such factors is represented by specific tumor-dependent one; the second category includes general pathological risk factors; the third does therapy-dependent risk factors. Conclusion. Malignant neoplasms are a risk factor for thrombotic events while hemostatic system activation promotes tumor growth and metastasis.

Full Text

Restricted Access

About the authors

Alexander Viktorovich Vorobyev

I.M. Sechenov First Moscow State Medical University

Email: alvorobev@gmail.com
Candidate of Medical Sciences, Associate Professor of the Department of Obstetrics and Gynecology of the Faculty of Medical Prevention

Alexander Davidovich Makatsaria

I.M. Sechenov First Moscow State Medical University

Email: gemostasis@mail.ru
Corresponding Member of the Russian Academy of Sciences, Professor, Doctor of Medical Sciences, Head of the Department of Obstetrics and Gynecology of the Faculty of Medical Prevention

Viktoria Omarovna Bitsadze

I.M. Sechenov First Moscow State Medical University

Email: gemostasis@mail.ru
Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology of the Faculty of Medical Prevention

Benjamin Brenner

Institute of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus

Email: gemostasis@mail.ru
Professor, Director Haifa, Israel

References

  1. Воробьев А.В., Макацария А.Д., Чабров А.М., Савченко А.А. Синдром Труссо. Современный взгляд на проблему. Журнал акушерства и женских болезней. 2015; 64(4): 85-94. [Vorobyev A.V., Makatsariya A.D., Chabrov A.M., Savchenko A.A. Tissot syndrome. A modern view of the problem. Zhurnal akusherstva i zhenskih bolezney. 2015; 64(4): 85-94. (in Russian)]
  2. Dammacco F., Vacca A., Procaccio P., Ria R., Marech I., Racanelli V. Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a singlecenter of internal medicine. Clin. Exp. Med. 2013; 13(2): 85-97.
  3. Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 2001; 106(1-2): 33-42.
  4. Demers M., Wagner D.D. NETosis: a new factor intumor progression and cancer-associated thrombosis. Semin. Thromb. Hemost. 2014; 40(3): 277-83.
  5. Davila M., Robles-Carrillo L., Unruh D., Huon Q., Gardiner C., Sargent I.L. et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J. Thromb. Haemost. 2014; 12: 186-96.
  6. Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. M.: Триада-Х; 2008. [Makatsariya A. D., Vorobyev A.V., Bitsadze V.O. Malignant neoplasms, thrombophilia, thromboses. Monograph. Moscow: Triada-X; 2008. (in Russian)]
  7. Langer F., Bokemeyer C. Crosstalk between cancerand haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie. 2012; 32(2): 95-104.
  8. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oacogene. 2003; 22(42): 6524-36.
  9. Макацария А.Д., Воробьев А.В. Гемостазиологические аспекты опухолевого роста. Акушерство и гинекология. 2016; 9: 28-36. http://dx.doi.org/10.18565/ aig.2016.9.28-36 [Makatsaria A.D., Vorobyev A.V. Hemostasiological aspects of tumor growth. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (9): 28-36. (in Russian) http://dx.doi.org/10.18565/ aig.2016.9.28-36]
  10. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2004; 2: 1266-71.
  11. Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin. Thromb. Hemost. 2003; 29: 239-46.
  12. Mackman N. New insights into the mechanisms of 'venous thrombosis. J. Clin. Invest. 2012; 122(7): 2331-6.
  13. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6(6): 401-10.
  14. Hernândez C., Orbe J., Roncal C., Alvarez-Hernandez M., Martinez de Lizarrondo S., Alves M.T. et al. Tissue factorexpressed by microparticles is associated withmortality but not with thrombosis in cancer patients. Thromb. Haemost. 2013; 110(3): 598-608.
  15. Buller H.R., van Doormaal F.F., van Sluis G.L., Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J. Thromb. Haemost. 2007; 5(Suppl. 1): 246-54.
  16. Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiol. Haemost. Thromb. 2006; 35(1-2): A20.
  17. Воробьев А.В., Макацария А.Д. Противотромботическая терапия у онкологических больных. Практическая медицина. 2014; 5: 18-28. [Vorobyev A.V., Makatsariya A.D. Anti-thrombotic therapy in cancer patients. Prakticheskaya meditsina. 2014; 5: 18-28. (in Russian)]
  18. Eikelboom J.W., Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Haemost. 2007; 5(Suppl. 1): 255-63.
  19. Falanga A. Mechanism of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998; 28(Suppl. 3): 50-60.
  20. Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. 2006; 95(3): 535-40.
  21. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 2000; 160(22): 3415-20.
  22. Geddings J.E., Mackman N. Tumor-derived tissuefactor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013; 122(11): 1873-80.
  23. Lee A.Y. Screening for occult cancer in patients with idiopathic venous thromboembolism: no. J. Thromb. Haemost. 2003; 1(11): 2273-4.
  24. Bauer K.A. New anticoagulants: anti IIa vs anti Xa--is one better? J. Thromb. Thrombolysis. 2006; 21(1): 67-72. http://link.springer.com/article/ 10.1007
  25. Bergqvist D., Agnelli G., Cohen A.T., Eldor A., Nilsson P.E., Le Moigne-Amrani A., Dietrich-Neto F.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 2002; 346(13): 975-80.
  26. Levine M.N., Lee A.Y. Treatment of venous thrombosis in the cancer patient. Acta Haematol. 2001; 106(1-2): 81-7.
  27. Claussen C., Rausch A. V., Spath B. et al. Clinical significance of hemostatic activation markers in women with suspected ovarian cancer. Oncol. Res. Treat. 2014; 37: V669.
  28. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484-8.
  29. Mousa S.A. Low-molecular-weight heparin in thrombosis and cancer. Semin. Thromb. Hemost. 2004; 30(Suppl. 1): 25-9.
  30. Van Doormaal F.F., Terpstra W., Van Der Griend R., Prins M.H., Nijziel M.R., Van De Ree M.A. et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J. Thromb. Haemost. 2011; 9(1): 79-84.
  31. Khorana A.A. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb. Res. 2012; 129: 10-5.
  32. Thaler J., Preusser M., Ay C., Kaider A., Marosi C., Zielinski C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb. Res. 2013; 131(2): 162-5.
  33. Borsig L., Wong R., Feramisco J. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA. 2001; 98(6): 3352-7.
  34. Воробьев А.В. Генетическая и приобретенная тромбофилия в патогенезе тромботических осложнений у онкологических пациентов. Акушерство, гинекология и репродукция. 2014; 8(4): 68. [Vorobyev A.V. Genetic and acquired thrombophilia in the pathogenesis of thrombotic complications in cancer patients. Akusherstvo, ginekologiya i reproduktsiya. 2014; 8 (4): 68. (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies